Last reviewed · How we verify
Afrin
At a glance
| Generic name | Afrin |
|---|---|
| Also known as | oxymetazoline hydrochloride |
| Sponsor | EMS |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients (NA)
- A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol (PHASE1, PHASE2)
- Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants (PHASE2)
- Vasopressor Impact on Brain Circulation, Organ Blood Flow and Tissue Oxygenation During Anesthesia (PHASE2, PHASE3)
- The GUARDIAN Pilot Trial (NA)
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery (PHASE4)
- Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury (NA)
- Deciphering Preserved Autonomic Function After Multiple Sclerosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |